Strategies for Combining Chemotherapy and Biotherapy in Melanoma

Landis S.H. , Murray T. , Bolden S. Cancer statistics, 1999. CA Cancer J Clin. 1999; 49: 8–31.

Anderson C.M. , Buzaid A.C. , Legha S.S. Systemic treatments for advanced cutaneous melanoma. Oncology. 1995; 9: 1149–1158.

Keilholz U. , Stoter G. , Punt J. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am. 1997; 3: S22–28.

Sparano J.A. , Fisher R.I. , Sunderland M. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993; 11: 1969–1977.

Buzaid A.C. , Legha S.S. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol. 1994; 21: 23–28.

Anderson C. , Buzaid A. , Ali-Osman F. Biochemotherapy in the treatment of advanced melanoma. In: Khayat D. , Hortobagyi G. , eds. Progress in Anti-Cancer Chemotherapy. Malden, MA: Blackwell Science; 1997: 68–87.

Richards J.M. , Mehta N. , Ramming K. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992; 10: 1338–1343.

Richards J.M. , Gale D. , Mehta N. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of metastatic melanoma. J Clin Oncol. 1999; 17: 651–657.

Antoine E.C. , Benhammouda A. , Bernard A. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am. 1997; 3: S16–S21.

Legha S. , Ring S. , Eton O. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998; 16: 1752–1759.

Legha S.S. , Ring S. , Bedikian A. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996; 7: 827–835.

Ron I.G. , Mordish Y. , Eisenthal A. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma. Cancer Immunol Immunother. 1994; 38: 379–384.

Atzpodien J. , Lopez Hänninen E. , Kirchner H. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995; 31A: 876–881.

Thompson J. , Gold P. , Markowitz D. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am. 1997; 3(suppl 1): S29–34.

Keilholz U. , Goey S.H. , Punt C.J. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997; 15: 2579–88.

Johnston S.R. , Constenla D.O. , Moore J. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer. 1998; 77: 1280–1286.

Dorval T. , Negrier S. , Chevreau C. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer multicenter, parallel study. Cancer. 1999; 85: 1060–1066.

Rosenberg S.A. , Yang J.C. , Schwartzentruber D.J. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999; 17: 968–975.

Rosenberg B. Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep. 1975; 59: 589–598.

Kleinerman E.S. , Zwelling L.A. , Muchmore A.V. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloro-platinum(II). Cancer Res. 1980; 40: 3099–3102.

Sodhi A. , Pai K. , Singh R.K. Activation of human NK cells and monocytes with cisplatin in vitro. Int J Immunopharmacol. 1990; 12: 893–898.

Sodhi A. , Geetha B. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide, and recombinant interferon-gamma on murine macrophages in vitro. II. Nat Immun Cell Growth Regul. 1989; 8: 108–116.

Kleinerman E.S. , Zwelling L.A. , Howser D. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet. 1980; 2: 1102–1105.

Lower E.E. , Baughman R.P. The effect of cancer and chemotherapy on monocyte function. J Clin Lab Immunol. 1990; 31: 121–125.

Lichtenstein A.K. , Pende D. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res. 1986; 46: 639–644.

Sodhi A. , Basu S. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565. Nat Immun. 1992; 11: 105–116.

Crum D.E. Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol Immunother. 1993; 36: 18–24.

Arinaga S. , Adachi M. , Karimine N. Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients. Int J Immunopharmacol. 1994; 16: 519–524.

Tsuda H. , Kitahashi S. , Umesaki N. Abrogation of suppressor cells activity by cis-diamminedichloroplatinum (CDDP) treatment using therapeutic doses in ovarian cancer patients. Gynecol Oncol. 1994; 52: 218–221.

Mizutani Y. , Bonavida B. , Nio Y. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer. 1993; 71: 1313–1321.

Mizutani Y. , Nio Y. , Yoshida O. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. J Urol. 1992; 147: 505–510.

Collins J.L. , Kao M.S. The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother. 1989; 29: 17–22.

Mally M.B. , Taylor R.C. , Callewaert D.M. Effects of platinum agents on in vitro assays of human antitumor immunity. II. Effects of cis-[Pt(NH3)2Cl2] on spontaneous cell-mediated cytotoxicity. Chemotherapy. 1980; 26: 1–6.

Bernsen M.R. , Van Barlingen H.J. , Van der Velden A.W. Dualistic effects of cis-diammine-dichloro-platinum on the antitumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon. Int J Cancer. 1993; 54: 513–517.

Maguire H.C. Jr , Ettore V.L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol. 1967; 48: 39–43.

Berd D. , Mastrangelo M.J. , Engstrom P.F. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 1982; 42: 4862–4866.

Watanabe M. , Kawano Y. , Kubota T. Mechanism of synergistic antitumor effects of mitomycin-C, 5-fluorouracil and interleukin-2 against human colon cancer. Proc Am Assoc Cancer Res. 1995; 36: 299.

Wadler S. , Schwartz E.L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990; 50: 3473–3486.

Johnson C.S. Modulation of chemotherapy antineoplastic agents with biologic agents: enhancement of antitumor activities by interleukin-1. Curr Opin Oncol. 1992; 4: 1108–15.

Benchekroun M.N. , Parker R. , Reed E. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha. Biochem Biophys Res Commun. 1993; 195: 294–300.

Parmiani G. , Rivoltini L. Biologic agents as modifiers of chemotherapeutic effects. Curr Opin Oncol. 1991; 3: 1078–1086.

Lejeune F. , Lienard D. , Eggermont A. Rationale for using TNF-alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem. 1994; 56: 52–61.

Braunschweiger P.G. , Basrur V.S. , Santos O. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors. Cancer Res. 1993; 53: 1091–1097.

Braunschweiger P. , Basrur V. , Santos O. Interleukin-1 alpha induced oxidants increase cisplatin cytotoxicity in squamous cell carcinoma cells in vitro. Proc Annu Meet Am Assoc Cancer Res. 1993; 34: A2778.

Maragos C.M. , Wang J.M. , Hrabie J.A. Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res. 1993; 53: 564–568.

Braunschweiger P. , Cameron D. , Sharp L. Cisplatin and nitric oxide have synergistic cytotoxicity in cP resistant human melanoma cells. Proc Annu Meet Am Assoc Cancer Res. 1996; 37: 404.

Moncada S. , Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002–2012.

Chang M.J. , Modzelewski R.A. , Russel D.M. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res. 1996; 56: 886–891.

Thomsen L.L. , Baguley B.C. , Rustin G.J. Flavone acetic acid (FAA) with recombinant interleukin-2 (IL-2) in advanced malignant melanoma. II. Induction of nitric oxide production. Br J Cancer. 1992; 66: 723–727.

Gauny S. , Zimmerman R. , Winkelhake J. Combination therapies using interleukin-2 and chemotherapeutics in murine tumors. Proc Annu Meet Am Assoc Cancer Res. 1989; 30: 372.

Rinehart J.J. , Triozzi P.L. , Lee M.H. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model. Mol Biother. 1992; 4: 77–82.

Formelli F. , Rossi C. , Sensi M.L. Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer. 1988; 42: 952–957.

Lumsden S. , Codde J. , Gay B. Influence of schedule on the therapeutic efficacy of chemoimmunotherapy with doxorubicin and interleukin-2. Biotherapy. 1992; 5: 113–118.

Nakamura S. , Kashimoto S. , Kajikawa F. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice. Cancer Res. 1991; 51: 215–221.

Braunschweiger P.G. , Jones S.A. , Johnson C.S. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res. 1991; 51: 5454–5460.

Chang M.J. , Yu W.D. , Reyno L.M. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in RIF-1 tumor model. Cancer Res. 1994; 54: 5380–5386.